# Selank research guide Selank is a synthetic heptapeptide (seven amino acids, sequence TKPRPGP; research name TP-7) developed in Russia at the Institute of Molecular Genetics, Russian Academy of Sciences, as a tuftsin analog with a Pro-Gly-Pro tail. Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use. - Identity: CAS 129954-34-3, molecular formula C33H57N11O9, molecular weight about 751.9 g/mol (Form Labs catalogue record). - Human record: one Russian clinical study in 62 patients with generalized anxiety disorder or neurasthenia, comparing Selank with medazepam (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008). - Mouse spleen: 34 of 84 inflammation-related genes showed altered activity (Kolomin et al., Regulatory Peptides, 2011). - Form Labs supplies Selank as laboratory reference material, with a catalog lot record, for research use only. Matching current certification is unverified. 62: Patients with generalized anxiety disorder or neurasthenia in the Zozulya 2008 Russian clinical study comparing Selank with medazepam. A study-size record, not an efficacy claim and not a Form Labs product claim. (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008: https://pubmed.ncbi.nlm.nih.gov/18454096/) 7: Selank is described as a heptapeptide - a peptide built from seven amino acids (sequence TKPRPGP). An identity fact, not a Form Labs product claim. (Selank sequence identity (TKPRPGP)) 4: The first four amino acids, TKPR, match the tuftsin pattern. A structure record, not a Form Labs product claim. (Koroleva and Myasoedov, Biology Bulletin, 2019: https://doi.org/10.1134/S1062359019040071) 34: Inflammation-related genes with altered activity in mouse spleen in the Kolomin 2011 laboratory study. A mouse-tissue finding, not a Form Labs product claim. (Kolomin et al., Regulatory Peptides, 2011: https://doi.org/10.1016/j.regpep.2011.05.001) ## Why is Selank studied? Selank is studied because it is a synthetic heptapeptide, seven amino acids with the sequence TKPRPGP (Form Labs catalogue record), developed in Russia at the Institute of Molecular Genetics, Russian Academy of Sciences, as an analog of tuftsin. Selank keeps tuftsin's four-amino-acid start (Form Labs catalogue record) and adds a Pro-Gly-Pro tail. The evidence is mostly animal and laboratory research, plus Russian clinical literature in anxiety-related disorders. Mostly animal and laboratory research, plus Russian clinical records. Selank was developed in Russia at the Institute of Molecular Genetics, Russian Academy of Sciences, as a synthetic analog of tuftsin. Tuftsin is a short immune-signalling peptide with the sequence TKPR; Selank keeps that four-amino-acid start and adds a Pro-Gly-Pro tail for stability, giving the seven-amino-acid sequence TKPRPGP. The evidence base looks different from a Western drug-development programme. It includes Russian clinical literature in anxiety-related disorders, animal and cell work on GABA and monoamine systems, immune-marker papers on cytokines and inflammation genes, and biochemical enzyme studies. This guide treats those records as research context only, not as product claims or use guidance. ## What laboratory observations have Selank studies reported? Volkova et al. (Frontiers in Pharmacology, 2016) reported altered neurotransmission-related gene activity in rat brain tissue after Selank. Kolomin et al. (Regulatory Peptides, 2011) reported altered inflammation-related gene activity in mouse spleen. These are animal laboratory findings. The human serum enzyme record is biochemical research and does not establish clinical outcomes for the Form Labs material. Selank laboratory measurements ### Peptide identity The Form Labs catalogue record identifies Selank as TKPRPGP, a tuftsin analog with a Pro-Gly-Pro tail. ### Rat brain tissue Volkova et al. (Frontiers in Pharmacology, 2016) reported altered neurotransmission-related gene activity in rat brain tissue; these are laboratory observations. ### Mouse spleen tissue Kolomin et al. (Regulatory Peptides, 2011) reported altered inflammation-related gene activity in mouse spleen; this is an animal finding. | | | | --- | --- | | Research code | TKPRPGP (TP-7) | | Class | Synthetic tuftsin analog - the first four amino acids match tuftsin (TKPR), with a Pro-Gly-Pro tail added for stability. | | Molecule | A synthetic heptapeptide (seven amino acids). CAS 129954-34-3, molecular formula C33H57N11O9, molecular weight about 751.9 g/mol. | | Reported half-life | No clean pharmacological half-life is quoted here. The literature instead discusses structure-stability design and biochemical enzyme context, including enkephalin-degrading enzymes in human serum. | | Originator | Institute of Molecular Genetics, Russian Academy of Sciences (Russia) | | Approval status | developed and used in Russia as an anxiolytic and sold in Russian pharmacies, but not approved by the TGA (Australia) or the FDA (US), and no marketing authorisation in the EU. | ## What has Selank been studied for? Selank research includes a Russian clinical record in patients with generalized anxiety disorder or neurasthenia (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008), altered gene activity in rat brain tissue (Volkova et al., Frontiers in Pharmacology, 2016), and mouse-spleen gene measurements (Kolomin et al., Regulatory Peptides, 2011). The animal and biochemical findings remain distinct from the clinical record. ### Anxiety-related behaviour and clinical scales Studied in a Russian clinical record in generalized anxiety disorder and neurasthenia, tracking psychometric scales and serum enkephalin activity. Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008 ### Immune and cytokine markers Studied for immune-marker context, including IL-6, T-helper cytokine balance, IFN-alpha context, and inflammation-related gene expression. Uchakina et al., Zhurnal Nevrologii i Psikhiatrii, 2008; Kolomin et al., Regulatory Peptides, 2011 ### GABA and monoamine systems Studied for GABA ligand-receptor interaction and neurotransmission-gene context in laboratory and animal models. Vyunova et al., Neurochemical Journal, 2014; Volkova et al., Frontiers in Pharmacology, 2016 ### BDNF marker context Discussed in Selank physiology literature as part of nerve-growth-marker context; this guide does not quote a standalone human BDNF outcome. Koroleva and Myasoedov, Biology Bulletin, 2019 ### Enkephalin-degrading enzymes Kost et al. (Russian Journal of Bioorganic Chemistry, 2001) reported inhibition of enkephalin-degrading enzymes in human serum; this is a biochemical finding. Kost et al., Russian Journal of Bioorganic Chemistry, 2001 ## Published studies ## What did the Selank studies find? The five Selank studies cited in this guide are one Russian human study and four laboratory records. Zozulya et al. (Zhurnal Nevrologii i Psikhiatrii, 2008) studied 62 patients with generalized anxiety disorder or neurasthenia and compared Selank with medazepam. Kolomin et al. (Regulatory Peptides, 2011) reported 34 of 84 inflammation-related genes altered in mouse spleen. This guide draws no efficacy conclusion from the human record and does not treat it as a Western regulatory trial. ### The Russian human study in anxiety-related disorders Zozulya AA et al. - Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova - 2008 (PMID 18454096) Human clinical study (Russia) Zozulya et al. (Zhurnal Nevrologii i Psikhiatrii, 2008) compared Selank with medazepam over 14 days in 62 patients with generalized anxiety disorder or neurasthenia. | | | | --- | --- | | Studied in | 62 patients with generalized anxiety disorder or neurasthenia. | | Design | A 14-day clinical comparison with 30 patients in the Selank group and 32 in the medazepam group (Zozulya et al., 2008). | | Measured | Psychometric scales and serum enkephalin activity. | This is the human-research anchor for Selank in the Russian literature (Zozulya AA et al. - Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova - 2008 (PMID 18454096)). It records a study population, comparator, scales, and serum enkephalin activity, but this guide draws no efficacy conclusion from it and does not treat it as a Western regulatory trial (Zozulya AA et al. - Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova - 2008 (PMID 18454096)). https://doi.org/https://pubmed.ncbi.nlm.nih.gov/18454096/ ### Neurotransmission-gene context in rat frontal cortex Volkova A et al. - Frontiers in Pharmacology - 2016 Preclinical (rat) A rat frontal-cortex study measuring expression of neurotransmission-related genes after Selank exposure. | | | | --- | --- | | Studied in | Rat frontal cortex. | | Design | A preclinical gene-expression study focused on 84 neurotransmission-related genes. | | Measured | GABAergic and monoamine-related gene-expression context. | The study reported changes in neurotransmission-related gene activity in rat brain tissue (Volkova A et al. - Frontiers in Pharmacology - 2016). This is an animal laboratory record, not a claim about mood, anxiety, cognition, or any person (Volkova A et al. - Frontiers in Pharmacology - 2016). https://doi.org/10.3389/fphar.2016.00031 ### GABA ligand-receptor interaction study Vyunova TV et al. - Neurochemical Journal - 2014 Preclinical (cell-membrane binding) A laboratory study of Selank in GABA ligand-receptor interaction with nerve-cell plasma membranes. | | | | --- | --- | | Studied in | Nerve-cell plasma membranes. | | Design | A receptor-interaction and binding study. | | Measured | GABA ligand-receptor interaction and binding context. | The paper is included as a narrow GABA receptor-binding record (Vyunova TV et al. - Neurochemical Journal - 2014). It is not a claim that Selank changes anxiety, mood, or cognition in people (Vyunova TV et al. - Neurochemical Journal - 2014). https://doi.org/10.1134/S1819712414040114 ### Inflammation-gene expression in mouse spleen Kolomin TA et al. - Regulatory Peptides - 2011 Preclinical (mouse immune tissue) A mouse-spleen study measuring inflammation-related gene expression after Selank in an IFN-alpha context. | | | | --- | --- | | Studied in | Mouse spleen tissue. | | Design | A laboratory gene-expression study of 84 inflammation-related genes. | | Measured | Number and identity of inflammation-related genes with altered activity. | The study reported 34 of 84 inflammation-related genes with altered activity in mouse spleen (Kolomin TA et al. - Regulatory Peptides - 2011). This is a mouse-tissue laboratory finding, not a Form Labs product claim (Kolomin TA et al. - Regulatory Peptides - 2011). https://doi.org/10.1016/j.regpep.2011.05.001 ### Enkephalin-degrading enzyme context in human serum Kost NV et al. - Russian Journal of Bioorganic Chemistry - 2001 Biochemical assay A biochemical study measuring how Semax and Selank interact with enkephalin-degrading enzymes of human serum. | | | | --- | --- | | Studied in | Human serum enzyme assays. | | Design | An in-vitro biochemical enzyme study. | | Measured | Inhibition of enkephalin-degrading enzymes. | The paper reported that Semax and Selank inhibit enkephalin-degrading enzymes in human serum (Kost NV et al. - Russian Journal of Bioorganic Chemistry - 2001). This is biochemical context, not a claim about what the Form Labs material does in a person (Kost NV et al. - Russian Journal of Bioorganic Chemistry - 2001). https://doi.org/10.1023/A:1011373002885 ## What has Selank research not established? The Selank studies cited in this guide are laboratory work and one Russian clinical study (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008), not a Western Phase 1-3 programme. The research cited in this guide gives no direction for use in or on people or animals, and describes the molecule in general, not what a specific batch does. - Large Western clinical trials: there is no Phase 1-3 programme reviewed by the TGA, FDA, or EU regulators. - Any use in or on people or animals: none of the research on this page is a use direction. - What a specific batch does: the studies are about the molecule in general, not this vial. ## Is Selank approved, and where does the research stand? Selank's approval status is not stated here, because this guide's sources include no regulator record of an approval decision for it. Its research timeline runs from enkephalin-degrading enzyme work (Kost et al., Russian Journal of Bioorganic Chemistry, 2001) through a Russian clinical study in 62 patients (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008) to a review of Selank structure and physiology (Koroleva and Myasoedov, Biology Bulletin, 2019). - Russian development programme: Selank is developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a synthetic tuftsin analog with a Pro-Gly-Pro tail. - 2001: Kost and colleagues report biochemical work on Semax and Selank inhibiting enkephalin-degrading enzymes in human serum. - 2008: Zozulya and colleagues publish a Russian clinical study record in 62 patients with generalized anxiety disorder or neurasthenia. - 2008: Uchakina and colleagues publish immune-marker context for IL-6 and T-helper cytokine balance in anxiety-asthenic disorders. - 2011: Kolomin and colleagues report 34 of 84 inflammation-related genes altered in mouse spleen in a Regulatory Peptides study. - 2014: Vyunova and colleagues publish GABA ligand-receptor interaction work in Neurochemical Journal. - 2016: Volkova and colleagues publish rat frontal-cortex gene-expression work in Frontiers in Pharmacology. - 2019: Koroleva and Myasoedov publish a Biology Bulletin review covering Selank structure and physiology context. ## What does the Selank research mean, and what does it not? The Selank evidence base is mostly animal, cell, immune-marker and biochemical work, and the human anchor is Russian clinical literature in anxiety-related disorders (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008), not a Western drug-development programme. The 62-patient Zozulya record (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008) gives study size and comparator context, and this guide does not turn it into a claim that Selank treats anything or changes mood in people. ### Mostly animal and laboratory research, plus Russian clinical literature Most of the Selank evidence base is animal, cell, immune-marker, and biochemical work. The human anchor is Russian clinical literature in anxiety-related disorders, not a Western drug-development programme. ### No TGA or FDA approval, no EU marketing authorisation Selank was developed and used in Russia as an anxiolytic and sold in Russian pharmacies, but it is not approved by the TGA (Australia) or the FDA (US), and it has no marketing authorisation in the EU. Nothing here should be read as Western regulatory approval. ### The 62-patient record is not an efficacy claim The Zozulya study gives the human-study size and comparator context for the literature record. This guide does not turn that record into a claim that Selank treats anxiety-related disorders or changes mood in people. ### Where Form Labs fits This guide is a plain-English summary of published research that Form Labs did not run. It is not medical advice, not a product claim, and not use guidance. Form Labs supplies Selank strictly as reference material, with a catalog lot record, for laboratory research. Matching current certification is unverified. ## How is Selank handled as reference material? Selank is laboratory reference material, not for human consumption or veterinary use. Storage and lot checks follow the product label and any verified matching certificate of analysis (COA). This guide's catalogue record notes storage at 2-8 C and protection from light. Historical sample reports do not verify current lot identity, purity or release status. ### Research-use boundary Selank is supplied strictly for laboratory research. It is not for human, veterinary, medical, cosmetic, or any other use. ### COA and label Historical sample reports do not establish current identity, purity or release status. Matching current certification is unverified; historical sample reports do not verify this lot. ### Storage Supplied freeze-dried. Keep it at 2-8°C (fridge-cold) and out of light, following the vial label, any verified matching lab report for the batch, and the receiving lab's own written procedures. ## Plain-English definitions. ### Heptapeptide A peptide made from seven amino acids; Selank's sequence is TKPRPGP. ### TP-7 A research name used for Selank in the literature. ### Tuftsin A natural four-amino-acid peptide with the sequence Thr-Lys-Pro-Arg, written TKPR. ### Tuftsin analog A lab-made peptide designed around tuftsin's sequence pattern; Selank keeps TKPR and adds Pro-Gly-Pro. ### Pro-Gly-Pro tail The final three amino acids in Selank's sequence, described in the literature as a stability-related tail. ### BDNF Brain-derived neurotrophic factor - a protein researchers measure as a nerve-growth marker. ### GABA A signalling molecule named here only in receptor-interaction and neurotransmission-gene research. ### Monoamine A group of signalling chemicals that includes dopamine and serotonin. ### Cytokine An immune-system signalling protein measured in some Selank immune-marker papers. ### Research use only (RUO) A lab-only boundary: not for human consumption, veterinary, medical, or cosmetic use. ## What are the most common questions about Selank? Selank is a synthetic heptapeptide with the sequence TKPRPGP (Form Labs catalogue record), developed in Russia as an analog of the natural peptide tuftsin and studied mostly in animal and cell research. The most common questions about Selank cover its sequence, what it is studied for, whether it is a nootropic or anxiolytic, how it differs from Semax, and its Australian status. Form Labs supplies research-use-only reference material. ### What is Selank? Selank is a synthetic heptapeptide (a seven-amino-acid peptide) with the sequence TKPRPGP, developed in Russia at the Institute of Molecular Genetics as an analog of the natural peptide tuftsin. It is studied in published research for its role in anxiety-related behaviour and immune-marker (cytokine) systems, mostly in animal studies plus some Russian clinical research. Form Labs supplies Selank strictly as research-use-only reference material, not for human or veterinary use. ### What is the Selank peptide sequence? Selank's sequence is TKPRPGP (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic heptapeptide built as an analog of tuftsin. The first four amino acids match the tuftsin fragment (Thr-Lys-Pro-Arg), and a Pro-Gly-Pro tail is added to make the peptide more stable. It is also indexed in research as TP-7. Its chemical registry number is CAS 129954-34-3, molecular formula C33H57N11O9, molecular weight about 751.9 g/mol. ### What is Selank studied for in research? Selank is studied in research for anxiety-related behaviour, BDNF marker context, immune and cytokine markers, GABA-related binding, and serotonin or monoamine systems. The cited records are mostly animal, cell, immune-marker, and biochemical studies, plus Russian clinical literature. Those records are research context only, not Form Labs product claims or use guidance. ### Is Selank a nootropic or anxiolytic? Zozulya et al. (Zhurnal Nevrologii i Psikhiatrii, 2008) recorded clinical scales and serum enkephalin activity in patients with generalized anxiety disorder or neurasthenia. Volkova et al. (Frontiers in Pharmacology, 2016) reported gene measurements in rat brain tissue. These are different study settings; this guide draws no individual clinical conclusion from them. ### What's the difference between Selank and Semax? Selank and Semax are two different synthetic peptides. Selank is the sequence TKPRPGP, an analog of the peptide tuftsin, and is studied more in anxiety- and immune-marker research; Semax is the sequence MEHFPGP, an analog of a fragment of the hormone ACTH, and is studied mostly in neuroprotection and cognition research. Form Labs supplies both only as research-use-only reference material. ### How does Selank relate to BDNF / tuftsin / the immune system in research? Selank is a tuftsin analog, meaning its first four amino acids match tuftsin's TKPR sequence and the peptide adds a Pro-Gly-Pro tail. Published research discusses BDNF as a nerve-growth marker and immune-marker systems including IL-6, T-helper cytokine balance, IFN-alpha context, and inflammation-gene expression. Those are laboratory and literature measurements. ### Is Selank approved anywhere? Selank is developed and used in Russia as an anxiolytic and is sold in Russian pharmacies, but it is not approved by the Therapeutic Goods Administration (TGA) in Australia or the FDA in the United States, and it has no marketing authorisation in the European Union. Form Labs supplies it only as research-use-only reference material, not as a medicine and not for human or veterinary use. ### Is Selank legal in Australia? Selank has no individual entry in the October 2026 Poisons Standard (checked 1 October 2026), and absence from that document is never a permission. Form Labs supplies Selank strictly as laboratory research material, not for human or veterinary use. ### What does "for research use only" mean for Selank? Selank is supplied strictly as laboratory research material. This guide is a plain-English summary of published research that Form Labs did not run - not medical advice, not a product claim, and not guidance for any human or veterinary use. ### How is Selank handled and stored in a lab? Selank is supplied freeze-dried, and the handling notes call for storage at 2-8°C (fridge-cold), protected from light, with current matching certification unverified for lot SELANK-2506 where shown. Orders use Form Labs' standard bank-transfer prepay flow. Shipping is AU-only from Perth via Australia Post or CouriersPlease: $10 standard (5-7 days) or $20 Express (2-3 business days), with standard shipping free on orders of $250 or more. Express is always charged. Tracking is emailed when the parcel is lodged. ## References - Zozulya AA et al. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2008 - 62 patients with generalized anxiety disorder or neurasthenia; Selank 30 versus medazepam 32; psychometric scales and serum enkephalin activity. PMID 18454096. - Uchakina ON et al. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2008 - IL-6 and Th1/Th2 cytokine-balance context in anxiety-asthenic disorders. PMID 18577961. - Kolomin TA et al. Regulatory Peptides, 2011, 170(1-3):18-23 - mouse-spleen study of 84 inflammation genes, with 34 changed. DOI: 10.1016/j.regpep.2011.05.001 - Volkova A et al. Frontiers in Pharmacology, 2016, 7:31 - rat frontal-cortex study of 84 neurotransmission genes in GABAergic and monoamine context. DOI: 10.3389/fphar.2016.00031 - Vyunova TV et al. Neurochemical Journal, 2014, 8:259-264 - GABA ligand-receptor interaction and binding with nerve-cell plasma membranes. DOI: 10.1134/S1819712414040114 - Kost NV et al. Russian Journal of Bioorganic Chemistry, 2001, 27:156-159 - Semax and Selank inhibition of enkephalin-degrading enzymes of human serum. DOI: 10.1023/A:1011373002885 - Koroleva SV and Myasoedov NF. Biology Bulletin, 2019, 46:407-414 - Selank structure and physiology review; general background context. DOI: 10.1134/S1062359019040071 ![One box labelled Peptide joined by three lines to three boxes labelled GABA, Monoamine and Cytokine.](/assets/content/rc-one-peptide-three-systems.png) The Selank papers cited in this guide study GABA and monoamine systems (Volkova et al., Frontiers in Pharmacology, 2016) and immune and cytokine markers (Uchakina et al., Zhurnal Nevrologii i Psikhiatrii, 2008; Kolomin et al., Regulatory Peptides, 2011); these are study markers and lab systems. --- Canonical page: https://www.formlaboratories.com/research/selank Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide. - Site guide for agents: https://www.formlaboratories.com/llms.txt - Sitemap: https://www.formlaboratories.com/sitemap.xml - Full catalogue: https://www.formlaboratories.com/shop - Contact: hello@formlaboratories.com All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.